Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haleon plc (HLN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on both the London Stock Exchange and the New York Stock Exchange. Haleon files annual reports on Form 20-F and submits current reports on Form 6-K under the Securities Exchange Act of 1934. These filings cover topics such as trading statements, total voting rights and capital, board and committee changes, and transactions by persons discharging managerial responsibilities (PDMRs).
Recent 6-K filings include announcements on Haleon’s Q3 trading statement, regular updates on total voting rights and capital, and detailed notifications of share transactions under the company’s share reward plans by senior managers. Other filings describe governance developments, such as the appointment of a new Chair, changes to the Senior Independent Director role and committee memberships, and the evolution of Haleon’s operating model, including the creation of six Operating Units and new executive roles like Chief Growth Officer and Chief Transformation Officer.
Many filings contain an "About Haleon" section that reiterates the company’s profile as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other, along with examples of long-standing brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren.
On this page, investors can review Haleon’s SEC submissions as they are made available from EDGAR, while AI-powered tools on the platform can help summarise key points, highlight changes over time and surface information on areas such as capital structure, insider share dealings disclosed as PDMR transactions, and updates to the company’s governance and operating model.
Haleon plc announced on 15 September 2025 that it purchased 997,991 ordinary shares of each under the second tranche of its share buyback programme announced 31 July 2025. Of the purchased shares, 23,788 will be cancelled and 974,203 will be held as treasury shares. After settlement the company's registered share capital is 8,952,353,648 ordinary shares of each, with 2,501,961 held as treasury shares and 8,949,851,687 shares with voting rights.
The announcement notes a full trade breakdown is available via the provided RNS link and on the company's investor website.
Haleon plc reports the purchase and cancellation of 172,878 ordinary shares of £0.01 each under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, registered share capital is 8,952,651,173 ordinary shares, of which 1,580,205 are held as treasury shares, leaving 8,951,070,968 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on the company website.
Haleon plc (LSE/NYSE: HLN) disclosed a notification under the UK Market Abuse Regulation for a transaction by a Person Discharging Managerial Responsibilities (PDMR). The Company received the notice on 10 September 2025 and reported an executed trade of 34 matching shares at a price of £3.6182 per share. The filing is a routine regulatory disclosure of insider dealing activity and includes the Company’s principal office address in Weybridge, Surrey.
The document also lists Haleon’s consumer brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren, and directs readers to www.haleon.com for more information. The filing contains transaction detail limited to volume and price; other typical fields are present in template form but not populated with additional substantive data.
Haleon plc announced the purchase and cancellation of 1,590,000 ordinary shares under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, the company's registered share capital is 8,952,824,051 ordinary shares of £0.01 each, with 1,580,205 held as treasury shares, leaving 8,951,243,846 ordinary shares with voting rights. The announcement directs readers to a full trade breakdown under the Market Abuse Regulation and notes the notice does not constitute an offer for securities. Contact and investor website information are provided.
Haleon plc reports the purchase and cancellation of 1,200,000 ordinary shares under the second tranche of its share buyback programme announced 31 July 2025. After settlement the company's registered share capital is 8,954,414,051 ordinary shares of £0.01 each, with 1,580,205 held as treasury shares, leaving 8,952,833,846 ordinary shares with voting rights. The announcement notes a full breakdown of individual trades is available via the provided link and on the company website. The notice clarifies it is not an offer for securities and provides contact/signature details for the company secretary.
Haleon plc (LSE/NYSE:HLN) announced PDMR notifications describing grants of share awards under its Share Value Plan and Performance Share Plan. The Performance Share Plan (Interim) awards vest in March 2028 subject to continued employment and performance conditions covering the period ending 31 December 2027; the relevant performance targets were disclosed in Haleon’s 2024 Annual Report and Form 20-F. The Share Value Plan (Buyout) awards are subject to continued employment. All awards were made in line with Haleon’s Directors' Remuneration Policy and are subject to malus and clawback provisions.
The filing discloses aggregate award volumes including items of 192,571 and 405,911 (shares/ADS) and notes that some volumes are Nil where applicable. No financial amounts, prices, or additional compensation details are provided in this report.
Haleon plc announced on 05 September 2025 that it purchased and cancelled 353,360 ordinary shares of £0.01 each under the second tranche of its buyback programme announced 31 July 2025. After settlement the company's registered share capital is 8,955,614,051 ordinary shares, of which 3,880,205 are held as treasury shares, leaving 8,951,733,846 ordinary shares with voting rights. A full breakdown of individual trades is available at the provided RNS link and on the company website. The announcement states it does not constitute an offer or solicitation in any jurisdiction.
Haleon plc reports the purchase and cancellation of 354,000 ordinary shares of each under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, registered share capital is 8,955,967,411 ordinary shares, of which 3,880,205 are held as treasury shares, leaving 8,952,087,206 ordinary shares with voting rights. The announcement notes the trade venue (London Stock Exchange CBOE (UK)/CXE) and provides a link to a full breakdown of individual trades. The company also states this is not an offer for securities and that details are available on its investor website.
Haleon plc announced the purchase and cancellation of 2,900,000 ordinary shares under the second tranche of its share buyback programme. After settlement, the company’s registered share capital is 8,956,321,411 ordinary shares of £0.01 each, with 3,880,205 held as treasury shares, leaving 8,952,441,206 ordinary shares with voting rights. The company provided a link to a full breakdown of individual trades and noted the announcement does not constitute an offer for securities. The buyback transaction was executed on the London Stock Exchange and details are posted on the company website.
Haleon plc reported its total issued share capital and voting rights. The company has 8,959,221,411 ordinary shares of each, of which 3,880,205 are held in treasury, leaving 8,955,341,206 ordinary shares with voting rights. Shareholders and others with notification obligations should use the voting-rights figure as the denominator for FCA notification calculations and may send notifiable interests to company.secretary@haleon.com. The filing also provides a brief company description noting Haleon (LSE/NYSE: HLN) is a global consumer health company with major brands across Oral Health, VMS, Pain Relief, Respiratory, Digestive and Therapeutic Skin Health.
FAQ
What is the current stock price of Haleon (HLN)?
What is the market cap of Haleon (HLN)?
